Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5449]
News [12654]
Articles [175]
Editorials [5]
Conferences [248]
elearning [17]
Immune gene signatures for predicting response to neoadjuvant...
Dr Marta Casarrubios - Hospital Universitario Puerta de Hierro-Majadahonda...
Immune gene signatures for predicting response to neoadjuvant chemoimmunotherapy in NSCLC ( Dr Marta Casarrubios - Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain )
31 Mar 2022
METNET: A phase II trial of metformin in patients with well differentiated...
Dr João Glasberg - Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil
METNET: A phase II trial of metformin in patients with well differentiated neuroendocrine tumours ( Dr João Glasberg - Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil )
31 Mar 2022
Real-world increase in biomarker testing in lung cancer
Dr Virginia Calvo de Juan - Hospital Universitario Puerta de Hierro-Majadahonda...
Real-world increase in biomarker testing in lung cancer ( Dr Virginia Calvo de Juan - Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain )
30 Mar 2022
EGFR testing: Best practice for NSCLC patients with exon 20 insertions
Dr Antonio Passaro, Dr Umberto Malapelle and Dr Joshua Sabari
EGFR testing: Best practice for NSCLC patients with exon 20 insertions ( Dr Antonio Passaro, Dr Umberto Malapelle and Dr Joshua Sabari )
30 Mar 2022
ASCO GU 2022: Latest in mHSPC
Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith
ASCO GU 2022: Latest in mHSPC ( Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith )
8 Mar 2022
Minimal residual disease in multiple myeloma
Prof Ola Landgren - University of Miami, Miami, USA
Minimal residual disease in multiple myeloma ( Prof Ola Landgren - University of Miami, Miami, USA )
8 Mar 2022
ASCO GU 2022: PARP inhibitors in prostate and MAGNITUDE
Dr Neal Shore and Prof Kim Chi
ASCO GU 2022: PARP inhibitors in prostate and MAGNITUDE ( Dr Neal Shore and Prof Kim Chi )
4 Mar 2022
An AI-derived digital pathology-based biomarker to predict the benefit of ADT...
Prof Daniel Spratt - University Hospitals Seidman Cancer Center, Cleveland, USA
An AI-derived digital pathology-based biomarker to predict the benefit of ADT in PC with validation in NRG/RTOG 9408 ( Prof Daniel Spratt - University Hospitals Seidman Cancer Center, Cleveland, USA )
3 Mar 2022
Survival outcomes of unilateral RB based on pathological risk stratification...
Dr Palwasha Rehman - Shaukat Khanum Memorial Cancer Hospital and Research...
Survival outcomes of unilateral RB based on pathological risk stratification-experience at a tertiary care centre in Pakistan ( Dr Palwasha Rehman - Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan )
1 Mar 2022
NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion
Prof Sam Chang - Vanderbilt University School of Medicine, Nashville, USA
NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion ( Prof Sam Chang - Vanderbilt University School of Medicine, Nashville, USA )
28 Feb 2022
Latest developments in mHSPC
Prof Kurt Miller and Prof Laura-Maria Krabbe
Latest developments in mHSPC ( Prof Kurt Miller and Prof Laura-Maria Krabbe )
25 Feb 2022
ASCO GU 2022: The latest in CRPC, including PARP combo data
Prof Eleni Efstathiou, Prof Gerhardt Attard, Prof Noel Clarke and Prof Axel...
ASCO GU 2022: The latest in CRPC, including PARP combo data ( Prof Eleni Efstathiou, Prof Gerhardt Attard, Prof Noel Clarke and Prof Axel Merseburger )
25 Feb 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation